Literature DB >> 26704557

Role of receptor occupancy assays by flow cytometry in drug development.

Jennifer J Stewart1, Cherie L Green2, Nicholas Jones3, Meina Liang4, Yuanxin Xu5, Danice E C Wilkins6, Maxime Moulard7, Kamila Czechowska8, David Lanham9, Thomas W McCloskey10, John Ferbas2, Barry W A van der Strate11, Carl-Magnus Högerkorp12, Timothy Wyant13, Alan Lackey3, Virginia Litwin14.   

Abstract

The measurement of the binding of a biotherapeutic to its cellular target, receptor occupancy (RO), is increasingly important in development of biologically-based therapeutic agents. Receptor occupancy (RO) assays by flow cytometry describe the qualitative and/or quantitative assessment of the binding of a therapeutic agent to its cell surface target. Such RO assays can be as simple as measuring the number of cell surface receptors bound by an antireceptor therapeutic agent or can be designed to address more complicated scenarios such as internalization or shedding events once a receptor engages the administered therapeutic agent. Data generated from RO assays can also be used to model whether given doses of an experimental therapeutic agent and their administration schedules lead to predicted levels of receptor occupancy and whether the receptor is modulated (up or down) on cells engaged by the therapeutic agent. There are a variety of approaches that can be used when undertaking RO assays and with the ability to measure distinct subsets in heterogeneous populations, flow cytometry is ideally suited to RO measurements. This article highlights the importance of RO assays on the flow cytometric platform in the development of biotherapeutic agents.
© 2016 The Authors Cytometry Part B: Clinical Cytometry Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  biomarker; biotherapeutic; flow cytometry; receptor occupancy; target binding

Mesh:

Substances:

Year:  2016        PMID: 26704557     DOI: 10.1002/cyto.b.21355

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  9 in total

1.  Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody.

Authors:  Yan Wang; Donghui Pan; Chenrong Huang; Bingliang Chen; Mingzhu Li; Shuaixiang Zhou; Lizhen Wang; Min Wu; Xinyu Wang; Yicong Bian; Junjie Yan; Junjian Liu; Min Yang; Liyan Miao
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

2.  Digital Receptor Occupancy Assay in Quantifying On- and Off-Target Binding Affinities of Therapeutic Antibodies.

Authors:  Chao-Kai Chou; Yen-Liang Liu; Yuan-I Chen; Po-Jung Huang; Pei-Hsiang Tsou; Chun-Te Chen; Heng-Huan Lee; Ying-Nai Wang; Jennifer L Hsu; Jin-Fong Lee; Thomas E Yankeelov; Jun Kameoka; Hsin-Chih Yeh; Mien-Chie Hung
Journal:  ACS Sens       Date:  2020-02-19       Impact factor: 7.711

3.  XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.

Authors:  Marsha L Crochiere; Stefan Hannus; Kerrin Hansen; Frank Becker; Erkan Baloglu; Margaret Lee; Michael Kauffman; Sharon Shacham; Yosef Landesman
Journal:  Oncotarget       Date:  2017-11-30

4.  Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles.

Authors:  A Rodallec; C Franco; S Robert; G Sicard; S Giacometti; B Lacarelle; F Bouquet; A Savina; R Lacroix; F Dignat-George; J Ciccolini; P Poncelet; R Fanciullino
Journal:  Sci Rep       Date:  2020-03-05       Impact factor: 4.379

Review 5.  Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.

Authors:  Maurits F J M Vissers; Jules A A C Heuberger; Geert Jan Groeneveld
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

6.  Optimization of Receptor Occupancy Assays in Mass Cytometry: Standardization Across Channels with QSC Beads.

Authors:  Gerd Haga Bringeland; Lucius Bader; Nello Blaser; Lisa Budzinski; Axel R Schulz; Henrik E Mei; Kjell-Morten Myhr; Christian A Vedeler; Sonia Gavasso
Journal:  Cytometry A       Date:  2019-01-27       Impact factor: 4.355

Review 7.  The Evolution of Single-Cell Analysis and Utility in Drug Development.

Authors:  Shibani Mitra-Kaushik; Anita Mehta-Damani; Jennifer J Stewart; Cherie Green; Virginia Litwin; Christèle Gonneau
Journal:  AAPS J       Date:  2021-08-13       Impact factor: 4.009

8.  A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1.

Authors:  Fabian Junker; Pratiksha Gulati; Uwe Wessels; Stefan Seeber; Kay-Gunnar Stubenrauch; Laura Codarri-Deak; Christoph Markert; Christian Klein; Priscila Camillo Teixeira; Henry Kao
Journal:  Cytometry A       Date:  2021-03-18       Impact factor: 4.355

9.  Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.

Authors:  Nishit B Modi; Xiaoli Cheng; Larry Mattheakis; Ching-Chang Hwang; Roya Nawabi; David Liu; Suneel Gupta
Journal:  Clin Pharmacol Drug Dev       Date:  2021-05-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.